REFRACTORY PLASMA CELL MYELOMA
Clinical trials for REFRACTORY PLASMA CELL MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PLASMA CELL MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PLASMA CELL MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus-Enhanced cocktail shows promise in stubborn myeloma
Disease control OngoingThis study is for people whose multiple myeloma has returned or stopped responding to at least three prior treatments. Researchers are testing whether adding a lab-modified virus (pelareorep) to a standard drug combination (bortezomib, dexamethasone, and pembrolizumab) can safely…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 17, 2026 17:02 UTC
-
New immune therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T cells) that are specially trained to recognize and attack cancer cells carrying a protein called MUC…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New combo attack on stubborn myeloma shows promise in early trial
Disease control OngoingThis study tests a two-part treatment plan for people with multiple myeloma that has come back or is not responding to therapy. First, patients receive daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this …
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New combo therapy targets Hard-to-Treat myeloma in early trial
Disease control OngoingThis early-phase study tests the safety and best dose of two drugs—venetoclax and tocilizumab—in people with a specific genetic subtype of multiple myeloma (t(11;14)) that has returned or stopped responding to treatment. The trial includes both African American and non-African Am…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control OngoingThis study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participant…
Matched conditions: REFRACTORY PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC